Immuno-Oncology

Ronald de Wit, MD, PhD, discusses the clinical implications of pembrolizumab in the non–muscle invasive bladder cancer patient population.

Asim Amin, MD, discusses the current role of checkpoint inhibitors in advanced renal cell carcinoma and where the future is heading in this space.

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, discusses the role of immunotherapy in prostate cancer.

The efficacy of combination therapy with a checkpoint inhibitor and chemotherapy has been proved in the triple-negative breast cancer space, and the additive and early toxicity may be worth the survival benefit, according to Lisa A. Carey, MD.

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the FDA approval of first-line pembrolizumab (Keytruda) in metastatic squamous non–small cell lung cancer regardless of PD-L1 expression.

The FDA has approved first-line pembrolizumab for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer.

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses how to manage toxicities associated with immunotherapy and tyrosine kinase inhibitor combinations in renal cell carcinoma.

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses a retrospective analysis of pembrolizumab (Keytruda) in patients with melanoma.

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the success of immunotherapy in small cell lung cancer.

Neil Morganstein, MD, discusses the intriguing PACIFIC results and the future role of immunotherapy in non–small cell lung cancer.

Peter Schmid, MD, PhD, shares the results of IMpassion130 and discussed his thoughts on the future of immunotherapy in breast cancer.

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses long-term survival of patients with non–small cell lung cancer (NSCLC) treated with pembrolizumab (Keytruda).

Ezra Cohen, MD, discusses the future role of immunotherapy in the treatment of patients with head and neck squamous cell carcinoma.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses immunotherapy combinations in kidney cancer.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses when to discontinue immunotherapy in patients with melanoma.

Hossein Borghaei, DO, MS, discusses immunotherapy selection for the treatment of patients with non–small cell lung cancer.

An interim analysis of an ongoing single-arm open-label phase II study showed encouraging antitumor activity with pembrolizumab (Keytruda) in patients with high-risk nonmuscle invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin.

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses next steps with immunotherapy in the treatment of patients with advanced renal cell carcinoma.

The poor long-term survival outcomes for patients with advanced renal cell carcinoma have prompted intensive clinical research aimed at developing novel therapeutic options addressing unmet needs.

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non–small cell lung cancer (NSCLC).

Ramsey N. Asmar, MD, discusses recent advances and next steps in small cell lung cancer.

First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.

The FDA has added 3 months to the review period for the combination of nivolumab plus low-dose ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dosing for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic urothelial carcinoma at the 2018 ESMO Congress.